Theravance Biopharma, Inc. (TBPH) Dividend History

Company News

• AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

  Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.

  Zacks Investment Research

  Featured Companies: ARQT HRTX
• Here's Why You May Invest in Theravance (TBPH) Stock Now

  Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.

  Zacks Investment Research

  Featured Companies: ALGS RAPT VTRS
• Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know

  The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research
• Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?

  Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research

  Featured Companies: ZTS
• Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates

  Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.

  Zacks Investment Research

  Featured Companies: THRD VTRS